THE NETHERLANDS – FEBRUARY 18, 2014 – SynAffix B.V., a protein engineering company focusing on the creation of next-generation Antibody-Drug Conjugates (ADCs), today announced the completion of its Series A investment round. Investors in the round are Aravis SA (Switzerland), BioGeneration Ventures (the Netherlands), MS Ventures, the corporate venture capital fund of Merck Serono and BOM Capital (the Netherlands).